Pharma channel feed

Bay­er scru­ti­nizes R&D group's pro­duc­tiv­i­ty as staffers fear lay­offs in wake of a re­vamp

8 years ago
R&D

Do­va picked up its new­ly ap­proved drug castoff for a song — but pay­ers will be singing the blues about the price

8 years ago

Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

8 years ago
R&D

Af­ter track­ing suc­cess in an­i­mals, neu­ro­sciences star De­nali moves ear­ly to bag an op­tion on a promis­ing tech for cross­ing the blood-brain bar­ri­er

8 years ago

Trump signs right-to-try bill, says 'mas­sive' vol­un­tary drug price cuts com­ing in two weeks

8 years ago

J&J hus­tles Leg­end’s promis­ing BC­MA CAR-T in­to PhI/II tri­al, win­ning an FDA green light to be­gin re­cruit­ing pa­tients

8 years ago
R&D

FDA moves Sage’s post­par­tum de­pres­sion drug brex­anolone in­to reg­u­la­tors’ busy pri­or­i­ty lane

8 years ago
R&D

FDA ex­e­cutes a 180 on Ther­a­peu­tic­sMD ther­a­py, hand­ing it an OK — and stok­ing con­cerns about po­lit­i­cal in­flu­ence

8 years ago

AS­CO loom­ing, Loxo, Bay­er line up a quick shot at FDA OK for their ground­break­ing ap­proach to can­cer ther­a­py

8 years ago

Those open of­fices bio­phar­ma ex­ecs love so much? Most staffers hate them with a pas­sion

8 years ago

Bio­Marin gets its shot at an­oth­er block­buster as FDA OKs rare dis­ease drug peg­valiase

8 years ago

Astel­las shed­ding 600-plus jobs as CEO shakes up R&D and sales ops in re­struc­tur­ing

8 years ago
R&D

Cara hauls in $70M on first leg of glob­al deal, set­ting up PhI­II kid­ney dis­ease drug for com­mer­cial roll out

8 years ago
R&D

House pass­es 'right-to-try' — al­low­ing the ter­mi­nal­ly ill to ask com­pa­nies for ex­per­i­men­tal drugs out­side of FDA's purview

8 years ago

FDA chief Got­tlieb is build­ing a reg­u­la­to­ry speed­way to ac­cel­er­ate gene ther­a­py de­vel­op­ment

8 years ago
Cell/Gene Tx

Al­ler­gan dou­bles down on NM­DA de­pres­sion drug de­vel­op­ment ef­forts, bag­ging an op­tion to a small mol­e­cule fol­lowup drug

8 years ago
R&D

New­com­er Do­va hus­tles a phar­ma castoff through to an FDA ap­proval, shares sink any­way

8 years ago

Wrestling with set­backs, Cel­gene adds $65M dis­cov­ery al­liance with Evotec to beef up on new can­cer drugs

8 years ago
R&D

Long side­lined on man­u­fac­tur­ing penal­ties, As­traZeneca fi­nal­ly gets a green light for a po­ten­tial hy­per­kalemia block­buster

8 years ago

Al­ler­gan faces fresh woes with Resta­sis patents as Wal­green, re­tail­ers file law­suit over 'an­ti­com­pet­i­tive con­duc­t'

8 years ago

Am­gen, No­var­tis ready to roll as FDA green lights block­buster cam­paign for mi­graine drug — priced at $6,900

8 years ago

Who’s de­lay­ing gener­ic com­pe­ti­tion? FDA pub­lish­es a long list of drug­mak­ers they say gamed the sys­tem

8 years ago

FDA faults IQVIA for er­rors in opi­oid sales da­ta, calls for qual­i­ty re­view

8 years ago

FDA ap­proves first non-opi­oid to treat with­draw­al symp­toms in adults

8 years ago
First page Previous page 300301302303304305306 Next page Last page
A service from the Financial Times